Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 1625 word(s) 1625 2021-10-12 05:37:55 |
2 format correction Meta information modification 1625 2021-10-21 04:00:40 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Greco, C. Nonalcoholic Fatty Liver Disease and Peripheral Diabetic Polyneuropathy. Encyclopedia. Available online: (accessed on 23 June 2024).
Greco C. Nonalcoholic Fatty Liver Disease and Peripheral Diabetic Polyneuropathy. Encyclopedia. Available at: Accessed June 23, 2024.
Greco, Carla. "Nonalcoholic Fatty Liver Disease and Peripheral Diabetic Polyneuropathy" Encyclopedia, (accessed June 23, 2024).
Greco, C. (2021, October 20). Nonalcoholic Fatty Liver Disease and Peripheral Diabetic Polyneuropathy. In Encyclopedia.
Greco, Carla. "Nonalcoholic Fatty Liver Disease and Peripheral Diabetic Polyneuropathy." Encyclopedia. Web. 20 October, 2021.
Nonalcoholic Fatty Liver Disease and Peripheral Diabetic Polyneuropathy

Peripheral diabetic polyneuropathy (DPN) is a microvascular complication of diabetes mellitus (DM), representing the most clinically relevant manifestation of typical forms of diabetic neuropathy (DN). DPN has been associated with another pathological condition linked to DM and obesity, the nonalcoholic fatty liver disease (NAFLD). NAFLD is a metabolically derangement-based liver disease, defined by the presence of steatosis in more than 5% of hepatocytes, in association with metabolic risk factors (such as obesity, diabetes, and dyslipidemia) and in the absence of excessive alcohol consumption or other chronic liver diseases.

NAFLD diabetes mellitus peripheral polyneuropathy

1. Introduction

Peripheral diabetic polyneuropathy (DPN) is a microvascular complication of diabetes mellitus (DM), representing the most clinically relevant manifestation of typical forms of diabetic neuropathy (DN). DPN has been defined by the Toronto Expert Panel on Diabetic Neuropathy as a symmetrical, length-dependent sensorimotor polyneuropathy attributable to metabolic and microvascular alterations, resulting from the chronic hyperglycemia typical of diabetes and cardiovascular risk covariates [1]. DPN occurs in at least 20% of people with type 1 DM (T1DM) after 20 years of disease duration, as suggested by large observational cohorts [2][3] and the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study [4][5]. Considering type 2 DM (T2DM), DPN has been detected in at least 10–15% of newly diagnosed patients with T2DM [6][7], and up to 50% after 10 years of disease duration [8][9]. Moreover, DPN has been identified in 11% to 23% of people with prediabetes [10]. From a clinical point of view, the DPN diagnosis is extremely relevant in DM management, since it confers a predisposition to pain, numbness, ulceration, and amputation of the distal extremities, increasing the risk of all-cause and cardiovascular disease mortality [11][12][13].
Starting from the clinical relevance of DPN, many authors tried to identify factors able to predict DPN in DM. Till now, diabetes duration and glycemic control, expressed by glycated hemoglobin (HbA1c), represent the main predictive factors [14]. Moreover, metabolic syndrome components, such as hypertriglyceridemia, hypertension, abdominal obesity, and low high-density lipoprotein (HDL) serum levels, are consistently associated with DPN in both T2DM and T1DM [15][16]. Alongside metabolic variables, several lifestyle habits have been detected as further correlates, such as smoking, alcohol abuse, height, and older age [15]. In general, many studies suggested that DPN prevalence was higher in cases of concomitant comorbid conditions, such as micro- (nephropathy or retinopathy), macro- vascular disease (peripheral arterial disease or cardiovascular disease) and depression [17]. Finally, new biochemical markers have been investigated as potential predictive markers of DPN. In particular, novel systemic biomarkers of oxidative stress (i.e., reactive oxygen species), inflammation (interleukin (IL)-6, and tumor necrosis factor (TNF)-a), and vascular activation, have been linked to distal DPN development [16].
Recently, DPN has been associated with another pathological condition linked to DM and obesity, the nonalcoholic fatty liver disease (NAFLD). NAFLD is a metabolically derangement-based liver disease, defined by the presence of steatosis in more than 5% of hepatocytes, in association with metabolic risk factors (such as obesity, diabetes, and dyslipidemia) and in the absence of excessive alcohol consumption or other chronic liver diseases [18][19]. NAFLD affects more than 25% of the global population [20] and is largely demonstrated as highly prevalent in patients with T2DM (60–75%) [21]. Many studies proved that NAFLD is associated with an increased risk of macro- and micro-vascular complications in diabetic patients [22][23][24], notably including albuminuria [25] and retinopathy [26]. Currently, there is little information about the association between NAFLD and DPN, and the available data are scarce and conflicting.

2. Current Insights

Several studies have been designed to explore the impact of NAFLD on DPN prevalence in both T1DM and T2DM patients so far, but this is the first attempt to systematically combine these results together in a meta-analysis. We demonstrate that DPN is more frequent when NAFLD is associated to DM, evaluating more than 9000 diabetic subjects. This result has an immediate clinical translation. Indeed, we clearly demonstrate that a diabetic patient must be carefully evaluated for the onset of peripheral neurological complications, especially when NAFLD is associated with diabetes. This is particularly true in T2DM or in T1DM and advancing age. Indeed, we demonstrate that DPN risk in T1DM is higher when the diabetes duration is longer, confirming that the long disease duration could be a confounding factor for DPN development. Moreover, here we highlight how NAFLD in DM is strictly related to high BMI and diabetes duration, confirming how the prevention of the DM complications must necessarily involve attention to weight gain. In details, NAFLD determines a complex array of metabolic and extra-hepatic consequences, which result from the intra-hepatic deposition of ectopic fat. This condition strongly correlates with abdominal obesity, insulin resistance, and all components of metabolic syndrome. Notably, obesity is one of the clinical correlates of PND in DM2 people. Therefore, obesity itself could represent a confounding factor of the association between NAFLD and PND, at least in DM2.
The link between NAFLD and microvascular complications in diabetic patients is based so far only on association studies, but the cause-effect relationship is far from being completely elucidated. In particular, NAFLD has been suggested as an independent predictor for diabetic kidney disease and proliferative diabetic retinopathy in patients with T2DM [27][28], while the association with DPN is more debated. Thus, NAFLD has been considered as a risk factor for organ-specific complications of DM. What is largely supposed is that NAFLD could exacerbate insulin resistance, impairs dyslipidemia, and predisposes vessels to atherogenic damages, throughout the release of pro-inflammatory, pro-coagulant, and pro-atherogenic factors [29][30][31]. Moreover, NAFLD induces those damages leading to endothelial dysfunction, predisposing to vascular diseases [32].
In particular, considering DPN, the pathogenetic relationship with NAFLD is still under debate. From one side, the metabolic asset leading to NAFLD is largely considered among the risk factors for DPN development. Moreover, in addition to the known metabolic correlates, the possible molecular mediators linking NAFLD with DPN could include the increased release of some pathogenic mediators from the liver, such as advanced glycation end-products, reactive oxygen species, C reactive protein, IL-6, and TNF-α, as also suggested for retinopathy and chronic kidney disease [28].
NAFLD natural history describes early stages, typically asymptomatic, with only incidental finding of abnormal liver enzymes, such as raised plasma alanine aminotransferase (ALT), aspartate transaminase (AST), and/or gamma-glutamyltransferase (γGT) [33]. However, since liver enzymes largely fluctuate in NAFLD patients, they are not routinely considered as clinical markers of NAFLD diagnosis or severity [18][34][35]. Thus, the use of imaging techniques, such as ultrasound, is generally applied as a first line diagnostic step in evaluating hepatic steatosis, also considering its safety and availability, and low cost [36]. With this in mind and considering the main result of our meta-analysis, it is clear that diabetic patients must undergo hepatic ultrasound evaluation in order to precociously detect the presence of NAFLD. However, NAFLD severity could also have a role in comorbidities development. The gold standard to detect NAFLD severity, in terms of steatosis amount, necro-inflammation, and fibrosis is represented by liver biopsy [18] that is not suitable for large-scale screening purposes, due to invasiveness and costs. Several emerging non-invasive techniques, notably including composite biomarkers, ultrasound elastography, or magnetic resonance, display good performance in evaluating NAFLD severity and have been proposed for widespread use in clinical practice. Unfortunately, only a minority of studies enrolled in our meta-analysis evaluated NAFLD severity, preventing us from a reliable analysis of such data. Future studies should be designed to identify whether NAFLD severity could predict the DPN development.
The result of this meta-analysis provides a clear snapshot on what we know about the association among DM, NAFLD, and peripheral DPN. This setting, however, is very heterogeneous. Indeed, all studies enrolled are population-based matched case-control studies, with a clear difference among inclusion and exclusion criteria. Moreover, only in 7 out of 13 studies the aim of the study was the evaluation of the prevalence of micro-vascular complications in diabetic patients. In the remaining part, the peripheral DPN has been assessed in relation to specific clinic or biochemical characteristics of enrolled patients, such as uric acid or liver fibrosis. Thus, the approach to our study question (i.e., whether NAFLD predisposes to peripheral DPN in patients with DM) is widely different, limiting the robustness of a comprehensive evaluation. Moreover, the peripheral DPN can be probable and confirmed, according to the diagnostic path followed. In particular, only when NCS is performed, a confirmed diagnosis should be reached. Our meta-analysis collected only six studies in which a confirmed DPN could be verified, increasing the heterogeneity among studies. Furthermore, the clinical management of patients enrolled in each study is extremely variable. In particular, diabetic comorbidities and complications management could have a significant role in DPN development. Here, however, we could not adjust the meta-analytic approach with the therapies applied to enrolled patients. This could lead to confounding results considering secondary endpoints. As a confirmation, we highlight that lipid profile does not change between the study and control group, although several studies suggested a worse lipid profile in patients with NAFLD [37][38][39]. Thus, we could not speculate in favour or in contrast to dyslipidaemia as a factor linking NAFLD and peripheral neuropathy in diabetic patients.

3. Conclusions

The present meta-analysis suggests a significantly increased DPN prevalence among diabetic patients with NAFLD, in particular in the case of T2DM. Indeed, T2DM combined with NAFLD demonstrated a higher prevalence of peripheral DPN than the T2DM-alone group. This result has not been confirmed in T1DM, likely due to the longer duration of disease as a confounding factor. Moreover, our findings confirm that NAFLD in DM is strictly related to high BMI and also to diabetes duration. In conclusion, these results suggest that physicians should pay more attention to the early detection of DPN, especially in patients with NAFLD. Lastly, large-scale prospective studies are required to elucidate causal associations between NAFLD and the microvascular complications, including DPN, in diabetic people.


  1. Tesfaye, S.; Boulton, A.J.; Dyck, P.J.; Freeman, R.; Horowitz, M.; Kempler, P.; Lauria, G.; Malik, R.A.; Spallone, V.; Vinik, A.; et al. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010, 33, 2285–2293.
  2. Maser, R.E.; Steenkiste, A.R.; Dorman, J.S.; Nielsen, V.K.; Bass, E.B.; Manjoo, Q.; Drash, A.L.; Becker, D.J.; Kuller, L.H.; Greene, D.A. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989, 38, 1456–1461.
  3. Tesfaye, S.; Stevens, L.K.; Stephenson, J.M.; Fuller, J.H.; Plater, M.; Ionescu-Tirgoviste, C.; Nuber, A.; Pozza, G.; Ward, J.D. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM Complications Study. Diabetologia 1996, 39, 1377–1384.
  4. Martin, C.L.; Albers, J.W.; Pop-Busui, R.; DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014, 37, 31–38.
  5. Albers, J.W.; Herman, W.H.; Pop-Busui, R.; Feldman, E.L.; Martin, C.L.; Cleary, P.A.; Waberski, B.H.; Lachin, J.M.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010, 33, 1090–1096.
  6. Young, M.J.; Boulton, A.J.; MacLeod, A.F.; Williams, D.R.; Sonksen, P.H. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993, 36, 150–154.
  7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352, 837–853.
  8. Ang, L.; Jaiswal, M.; Martin, C.; Pop-Busui, R. Glucose control and diabetic neuropathy: Lessons from recent large clinical trials. Curr. Diabetes Rep. 2014, 14, 528.
  9. Pop-Busui, R.; Lu, J.; Brooks, M.M.; Albert, S.; Althouse, A.D.; Escobedo, J.; Green, J.; Palumbo, P.; Perkins, B.A.; Whitehouse, F.; et al. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care 2013, 36, 3208–3215.
  10. Papanas, N.; Vinik, A.I.; Ziegler, D. Neuropathy in prediabetes: Does the clock start ticking early? Nat. Rev. Endocrinol. 2011, 7, 682–690.
  11. Forsblom, C.M.; Sane, T.; Groop, P.H.; Tötterman, K.J.; Kallio, M.; Saloranta, C.; Laasonen, L.; Summanen, P.; Lepäntalo, M.; Laatikainen, L.; et al. Risk factors for mortality in Type II (non-insulin-dependent) diabetes: Evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia 1998, 41, 1253–1262.
  12. Soedamah-Muthu, S.S.; Chaturvedi, N.; Witte, D.R.; Stevens, L.K.; Porta, M.; Fuller, J.H.; EURODIAB Prospective Complications Study Group. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: The EURODIAB Prospective Complications Study (PCS). Diabetes Care 2008, 31, 1360–1366.
  13. Coppini, D.V.; Bowtell, P.A.; Weng, C.; Young, P.J.; Sönksen, P.H. Showing neuropathy is related to increased mortality in diabetic patients—A survival analysis using an accelerated failure time model. J. Clin. Epidemiol. 2000, 53, 519–523.
  14. Tesfaye, S.; Chaturvedi, N.; Eaton, S.E.; Ward, J.D.; Manes, C.; Ionescu-Tirgoviste, C.; Witte, D.R.; Fuller, J.H.; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N. Engl. J. Med. 2005, 352, 341–350.
  15. Feldman, E.L.; Callaghan, B.C.; Pop-Busui, R.; Zochodne, D.W.; Wright, D.E.; Bennett, D.L.; Bril, V.; Russell, J.W.; Viswanathan, V. Diabetic neuropathy. Nat. Rev. Dis. Prim. 2019, 5, 41.
  16. Bönhof, G.J.; Herder, C.; Strom, A.; Papanas, N.; Roden, M.; Ziegler, D. Emerging Biomarkers, Tools, and Treatments for Diabetic Polyneuropathy. Endocr. Rev. 2019, 40, 153–192.
  17. Ziegler, D.; Papanas, N.; Vinik, A.I.; Shaw, J.E. Epidemiology of polyneuropathy in diabetes and prediabetes. Handb. Clin. Neurol. 2014, 126, 3–22.
  18. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016, 64, 1388–1402.
  19. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S.A.; Brunt, E.M.; Sanyal, A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018, 67, 328–357.
  20. Younossi, Z.M.; Corey, K.E.; Lim, J.K. AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2021, 160, 912–918.
  21. Younossi, Z.M.; Koenig, A.B.; Abdelatif, D.; Fazel, Y.; Henry, L.; Wymer, M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016, 64, 73–84.
  22. Alkagiet, S.; Papagiannis, A.; Tziomalos, K. Associations between nonalcoholic fatty liver disease and ischemic stroke. World J. Hepatol. 2018, 10, 474–478.
  23. Targher, G.; Bertolini, L.; Padovani, R.; Poli, F.; Scala, L.; Tessari, R.; Zenari, L.; Falezza, G. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet. Med. 2006, 23, 403–409.
  24. Targher, G.; Bertolini, L.; Padovani, R.; Rodella, S.; Tessari, R.; Zenari, L.; Day, C.; Arcaro, G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007, 30, 1212–1218.
  25. Wijarnpreecha, K.; Thongprayoon, C.; Boonpheng, B.; Panjawatanan, P.; Sharma, K.; Ungprasert, P.; Pungpapong, S.; Cheungpasitporn, W. Nonalcoholic fatty liver disease and albuminuria: A systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 2018, 30, 986–994.
  26. Song, D.; Li, C.; Wang, Z.; Zhao, Y.; Shen, B.; Zhao, W. Association of non-alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: A meta-analysis of observational studies. J. Diabetes Investig. 2020, 12, 1471–1479.
  27. Casoinic, F.; Sâmpelean, D.; Bădău, C.; Prună, L. Nonalcoholic fatty liver disease--a risk factor for microalbuminuria in type 2 diabetic patients. Rom. J. Intern. Med. 2009, 47, 55–59.
  28. Targher, G.; Bertolini, L.; Rodella, S.; Zoppini, G.; Lippi, G.; Day, C.; Muggeo, M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008, 51, 444–450.
  29. Bugianesi, E.; McCullough, A.J.; Marchesini, G. Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology 2005, 42, 987–1000.
  30. Buzzetti, E.; Pinzani, M.; Tsochatzis, E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metab. Clin. Exp. 2016, 65, 1038–1048.
  31. Tilg, H.; Moschen, A.R. IL-1 cytokine family members and NAFLD: Neglected in metabolic liver inflammation. J. Hepatol. 2011, 55, 960–962.
  32. Santi, D.; Spaggiari, G.; Greco, C.; Lazzaretti, C.; Paradiso, E.; Casarini, L.; Potì, F.; Brigante, G.; Simoni, M. The “Hitchhiker’s Guide to the Galaxy” of Endothelial Dysfunction Markers in Human Fertility. Int. J. Mol. Sci. 2021, 22, 2584.
  33. Dyson, J.K.; Anstee, Q.M.; McPherson, S. Non-alcoholic fatty liver disease: A practical approach to diagnosis and staging. Front. Gastroenterol. 2014, 5, 211–218.
  34. McPherson, S.; Stewart, S.F.; Henderson, E.; Burt, A.D.; Day, C.P. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010, 59, 1265–1269.
  35. Mofrad, P.; Contos, M.J.; Haque, M.; Sargeant, C.; Fisher, R.A.; Luketic, V.A.; Sterling, R.K.; Shiffman, M.L.; Stravitz, R.T.; Sanyal, A.J. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37, 1286–1292.
  36. Ballestri, S.; Nascimbeni, F.; Lugari, S.; Lonardo, A.; Francica, G. A critical appraisal of the use of ultrasound in hepatic steatosis. Expert Rev. Gastroenterol. Hepatol. 2019, 13, 667–681.
  37. Deprince, A.; Haas, J.T.; Staels, B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol. Metab. 2020, 42, 101092.
  38. Elosua-Bayés, I.; Beloqui Ruiz, Ó. Association between non alcoholic fatty liver disease, metabolic and vascular risk. Clin. Investig. Arter. 2020, 32, 200–205.
  39. Chen, T.P.; Lai, M.; Lin, W.Y.; Huang, K.C.; Yang, K.C. Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: A community-based study. J. Gastroenterol. Hepatol. 2020, 35, 1636–1643.
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 458
Revisions: 2 times (View History)
Update Date: 21 Oct 2021
Video Production Service